• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [19189 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Betibeglogene autotemcel (β-thalassaemia) (treatment costs)]
2020     NIHR Health Technology Assessment programme Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT
2020     NIHR Health Technology Assessment programme Cancer diagnostic tools to aid decision-making in primary care: mixed-methods systematic reviews and cost-effectiveness analysis
2020     Center for Evidence-based Practice (CEP) Adverse effects of messenger RNA vaccines
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of ozanimod (Zeposia®) for the treatment of adult patients with relapsing-remitting multiple sclerosis (RRMS)
2020     NIHR Health Services and Delivery Research programme Identifying appropriate symbol communication aids for children who are non-speaking: enhancing clinical decision making
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [State of practice: evolving portrait of the use and clinical outcomes of transcatheter aortic valve implantation (TAVI) in Québec, an evaluation in the real-world context of care, 2013 to 2018]
2020     Center for Evidence-based Practice (CEP) Antibiotic prophylaxis for lower extremity wound debridement in the outpatient setting
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of amisulpride (Aktiprol®) for the treatment of schizophrenia
2020     NIHR Health Technology Assessment programme Surgical fixation compared with cast immobilisation for adults with a bicortical fracture of the scaphoid waist: the SWIFFT RCT
2020     NIHR Health Technology Assessment programme What is the effectiveness of varenicline compared with nicotine replacement therapy for long term smoking cessation and clinically important outcomes such as mortality, myocardial infarction and frequency of service use? Evidence from the Clinical Practice Research Datalink
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: RebinynTM (nonacog beta pegol) – coagulation factor IX (recombinant), notice of inclusion on the Liste des produits du système du sang du Québec]
2020     Center for Evidence-based Practice (CEP) Point of care vascular ultrasound
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice esketamine nasal spray (Spravato®) for the treatment of adults with treatment-resistant major depressive disorder
2020     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: recommendations concerning the information required to monitor nusinersen use in real-world settings]
2020     Center for Evidence-based Practice (CEP) Early mobilization to reduce medical inpatient length of stay and adverse
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Trastuzumab-emtansine (Kadcyla®) in adjuvant treatment of adult patients with HER-2 positive breast cancer in an early stage
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Indacaterol/glycopyrronium/mometasone (Enerzair® Breezhaler®) for maintenance treatment of asthma in adult patients
2020     NIHR Health Services and Delivery Research programme Identifying nurse-staffing requirements using the Safer Nursing Care Tool. Modelling the costs and consequences of real world application to address variation in patient need on hospital wards
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Atectura® Breezhaler® (indacaterol acetate/mometasone furoate)
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Burosumab (reassessment after the deadline: hypophosphataemia)]
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Advice reassessment osimertinib (Tagrisso®)
2020     NIHR Health Technology Assessment programme Seasonal Influenza Vaccination Effectiveness II (SIVE II): use of a large national primary care and laboratory-linked dataset to evaluate live attenuated and trivalent inactivated influenza vaccination effectiveness
2020     NIHR Public Health Research (PHR) programme Feasibility study of how best to engage obese men in narrative SMS (short message system) and incentive interventions for weight loss, to inform a future effectiveness and cost-effectiveness trial
2020     NIHR Health Technology Assessment programme Point-of-care creatinine tests to assess kidney function for outpatients requiring contrast-enhanced CT imaging: systematic reviews and economic evaluation
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Avelumab in combination with axitinib as a first-line treatment for adult patients with advanced renal cell carcinoma
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of ivacaftor/tezacaftor (Symkevi®) in combination with ivacaftor (Kalydeco®) for the treatment of cystic fibrosis
2020     NIHR Public Health Research (PHR) programme Healthy Dads, Healthy Kids UK: a cultural adaptation and feasibility study of a weight management programme for fathers of younger children
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Ibrutinib (Imbruvica®) for the treatment of Waldenstrom's disease
2020     NIHR Health Services and Delivery Research programme An evaluation of alcohol treatment centres: implications for service delivery, patient benefit and harm reduction
2020     Swiss Federal Office of Public Health (FOPH) Glinides and glitazones in the treatment of type 2 diabetes
2020     Andalusian Health Technology Assessment Area (AETSA) [Effectiveness and safety of the macrobiotic diet]
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Ibrutinib (Imbruvica®) for the treatment of adult patients with previously untreated chronic lymphatic leukaemia (CLL)
2020     NIHR Health Technology Assessment programme Spironolactone to improve exercise tolerance in people with permanent atrial fibrillation and preserved ejection fraction: the IMPRESS-AF RCT
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of Trifarotene (50 microgram/gram cream) (Aklief®) for the cutaneous treatment of acne vulgaris on the face and torso in patients aged 12 years and over
2020     NIHR Health Technology Assessment programme Examining the benefit of graduated compression stockings as an adjunct to low dose low molecular weight heparin in the prevention of venous thromboembolism in elective surgical inpatients identified as moderate or high risk for venous thromboembolism a multi-centre randomised controlled trial
2020     NIHR Health Services and Delivery Research programme Understanding how frontline staff use patient experience data for service improvement - an exploratory case study evaluation and national survey (US-PEx)
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Package advice dabrafenib/trametinib (Tafinlar®/Mekinist®)
2020     NIHR Health Services and Delivery Research programme Young people with Attention Deficit Hyperactivity Disorder (ADHD) in transition from children's services to adult services (Catch-uS): a mixed methods project using national surveillance, qualitative and mapping studies
2020     Norwegian Institute of Public Health (NIPH) [Hyperbaric oxygen therapy for radiation-induced cystitis]
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of oral semaglutide (Rybelsus®)
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Pentosan polysulfate sodium (Elmiron®) for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Givosiran (acute hepatic porphyria, ≥ 12 years)]
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) 12 SQ-HDM SLIT (Itulazax®) for the treatment of allergic rhinitis or conjunctivitis induced by pollen from the birch homologous group
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Olaparib (Lynparza®) for the maintenance treatment of adult patients with carcinoma of the ovaries, tubes or peritoneum (package advice)
2020     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Pharmacological treatment of common pain conditions in older persons]
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Trientine tetrahydrochloride (Cuprior®) [for] the treatment of Wilson's disease
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) GVS assessment of hydroquinine (Inhibin®) for patients with nocturnal muscle cramps
2020     European Network for Health Technology Assessment (EUnetHTA) Polatuzumab vedotin in combination with bendamustine and rituximab for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Voretigene neparvovec (Luxturna®) for the treatment of vision loss due to inherited retinal dystrophy with bi-allelic RPE65 mutations (package advice)
2020     The National Health Care Institute (ZIN, Zorginstituut Nederland) Bevespi® aerosphere 7.2 micrograms / 5 micrograms
2020     European Network for Health Technology Assessment (EUnetHTA) Siponimod for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity
2020     NIHR Health Services and Delivery Research programme Patient Experience And Reflective Learning (PEARL)
2020     European Network for Health Technology Assessment (EUnetHTA) Brolucizumab for the treatment of adults with neovascular (wet) age-related macular degeneration (AMD)
2020     European Network for Health Technology Assessment (EUnetHTA) Crizanlizumab for the prevention of vaso-occlusive crises in sickle cell disease patients aged 16 years and older
2020     NIHR Health Services and Delivery Research programme How do different neurodisability services meet the psychosocial support needs of children/young people with feeding disabilities and their families: a national survey and case study approach to mapping and costing service models, care pathways and the child and family experience
2020     European Network for Health Technology Assessment (EUnetHTA) Cefiderocol for the treatment of infections due to aerobic gram-negative bacteria in adult patients with limited treatment options
2020     European Network for Health Technology Assessment (EUnetHTA) Glasdegib in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy
2020     Malaysian Health Technology Assessment (MaHTAS) Targeted therapies in combination with hormonal therapy as a first-line treatment for HR+ and HER2- metastatic breast cancer
2020     European Network for Health Technology Assessment (EUnetHTA) Pretomanid in combination with bedaquiline and linezolid in adults for the treatment of pulmonary extensively drug-resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB)
2020     Malaysian Health Technology Assessment (MaHTAS) Refurbished medical device
2020     NIHR Health Technology Assessment programme Surgical treatments compared with early structured physiotherapy in secondary care for adults with primary frozen shoulder: the UK FROST three-arm RCT
2020     NIHR Health Services and Delivery Research programme Learning about and learning from GP Federations in the English NHS a qualitative investigation
2020     European Network for Health Technology Assessment (EUnetHTA) Remdesivir or the treatment of COVID-19. PICO and evidence gaps
2020     Malaysian Health Technology Assessment (MaHTAS) Resuscitative endovascular balloon occlusion of the aorta (REBOA)
2020     European Network for Health Technology Assessment (EUnetHTA) Remdesivir for the treatment of COVID-19
2020     Malaysian Health Technology Assessment (MaHTAS) Transbronchial cryobiopsy for lung biopsy in interstitial lung disease
2020     European Network for Health Technology Assessment (EUnetHTA) Dexamethasone for the treatment of hospitalised patients with COVID-19
2020     Malaysian Health Technology Assessment (MaHTAS) Hepatitis C virus screening and surveillance tests for dialysis patients
2020     NIHR Health Technology Assessment programme A multicentre randomised trial to establish the effect(s) of routine administration of fluoxetine in patients with a recent stroke (FOCUS)
2020     Malaysian Health Technology Assessment (MaHTAS) Strategies to eliminate mother to child transmission of hepatitis B in Malaysia
2020     NIHR Health Technology Assessment programme Effectiveness of progesterone to prevent miscarriage in women with early pregnancy bleeding: a randomised placebo-controlled trial (PRISM Trial: PRogesterone In Spontaneous Miscarriage Trial)
2020     Malaysian Health Technology Assessment (MaHTAS) Pneumococcal vaccination with 23-valent polysaccharide vaccine (PPV23) for elderly
2020     Health Technology Wales (HTW) Single-operator per-oral cholangioscopy for the management of hepatobiliary-pancreatic disorders
2020     Health Technology Wales (HTW) Virtual reality therapy for the management of procedure-related pain
2020     Health Technology Wales (HTW) Remote monitoring of blood glucose in women with gestational diabetes
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) Place des tests de diagnostic rapide dans la stratégie de prise en charge de la COVID-19
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) Chloroquine et Hydroxychloroquine dans le traitement de la COVID-19
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) Place des tests de diagnostic rapide dans la stratégie de prise en charge de la COVID-19 : Complément d’informations du 22 Mai 2020
2020     NIHR Health Technology Assessment programme Cognitive Rehabilitation for Attention and Memory in people with Multiple Sclerosis (CRAMMS)
2020     NIHR Public Health Research (PHR) programme Understanding the impact of tobacco tax increases and tobacco industry pricing on smoking behaviours and inequalities
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Tisagenlecleucel (reassessment after expiry: diffuse large B-cell lymphoma)]
2020     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Portrait of coronary revascularization by percutaneous coronary intervention and coronary bypass grafting in Quebec, 2015-2018]
2020     The Federal Joint Committee (G-BA) [Pharmaceutical Directive/Annex XII: Volanesorsen]
2020     NIHR Health Technology Assessment programme Annual mammographic screening to reduce breast cancer mortality in women from age 40 years: long-term follow-up of the UK Age RCT
2020     Andalusian Health Technology Assessment Area (AETSA) Cognitive training effectiveness for mild to moderate dementia patients. A systematic review
2020     National Authority for Assessment and Accreditation in Healthcare (INEAS) [Disinfection chambers/tunnels in the context of COVID-19 pandemic]
2020     Andalusian Health Technology Assessment Area (AETSA) Genetic risk prediction test for cardiovascular disease
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Clinical Efectiveness of Newborn Screening for Inborn Errors of Metabolism by MS/ MS. Update and pilot study assessment: Maple Syrup Urine Disease; Isovaleric Acidaemia; Homocystinuria]
2020     Andalusian Health Technology Assessment Area (AETSA) Efficacy, effectivity and safety of physical therapies for neuromuscular diseases: systematic review
2020     European Network for Health Technology Assessment (EUnetHTA) Hypoglossal nerve stimulation systems for treatment of obstructive sleep apnea
2020     Andalusian Health Technology Assessment Area (AETSA) Effectiveness and safety of MAGnetic Expansion Control (MAGEC) growing rods. Evidence Update.
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Treatment of benign thyroid by thermal laser or radiofrequency ablation]
2020     NIHR Health Technology Assessment programme Interventions for adults with a history of complex traumatic events: the INCiTE mixed-methods systematic review
2020     European Network for Health Technology Assessment (EUnetHTA) Biodegradable rectum spacers to reduce toxicity for prostate cancer
2020     NIHR Health Technology Assessment programme Thoracoscopy and talc poudrage compared with intercostal drainage and talc slurry infusion to manage malignant pleural effusion: the TAPPS RCT
2020     European Network for Health Technology Assessment (EUnetHTA) The 24-hour blood pressure measurement device Mobil-O-Graph® with the built-in algorithm ARCSolver® to measure arterial stiffness for the optimization of hypertension treatment and assessment of cardiovascular disease risk
2020     NIHR Health Technology Assessment programme Psychological interventions to improve self-management of type 1 and type 2 diabetes: a systematic review
2020     NIHR Health Technology Assessment programme Occupational advice to help people return to work following lower limb arthroplasty: the OPAL intervention mapping study
2020     NIHR Health Services and Delivery Research programme Medication management in older people: the MEMORABLE realist synthesis